MHRA authorises cancer treatment variation with an administration time of 3–5 minutesFeatured| MHRA| Nivolumab| under the skin injectionOn 30 April 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new under-the-skin ...
Cabo + nivo & ipi delays kidney cancer progressionCabozantinib| Ipilimumab| NivolumabAdding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
Kidney Cancer UK represents patients at NICE nivo+ipi appraisalIpilimumab| NICE| NivolumabOn 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...